Drugs / Xylometazoline
Xylometazoline
also known as
Otrivin · Balminil · Nazo-mist · Neo-synephrine ii · NSC-757378 · Otradrops · Otraspray · Otrivin hydrochloride · +7 more
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04732104 | Jul 2018 → Jun 2020 | — | Dow University of Health Sciences | Completed | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT06801522 | Dec 2024 → Mar 2025 overdue | — | Shaheed Mohtarma Benazir Bhutto Institue of Trauma | Recruiting | Missed primary |
| Phase 32 trials | ||||||
| Phase 3 | NCT03439436 | Feb → May 2018 | nasal cavity disorder | McNeil AB | Completed | No outcome recorded |
| Phase 3 | NCT00452270 | Mar → Apr 2007 | common cold | Novartis | Completed | No outcome recorded |
| Phase 42 trials · 1 missed | ||||||
| Phase 4 | NCT05556148 | Nov → Dec 2022 | common cold | HALEON | Completed | No outcome recorded |
| Phase 4 | NCT01351298 | Jun 2011 → Jun 2012 | — | Children's & Women's Health Centre of British Columbia | Completed | Missed primary |
| Phase not applicable5 trials | ||||||
| — | NCT07425938 | Jan → Apr 2026 overdue | — | University of Electronic Science and Technology of China | Recruiting | No outcome recorded |
| — | NCT03424889 | Jun → Dec 2018 | — | All India Institute of Medical Sciences | Completed | No outcome recorded |
| — | NCT03072173 | Mar 2017 → Jun 2018 | nasal disorder, obstructive sleep apnea syndrome | Lovisenberg Diakonale Hospital | Unknown | No outcome recorded |
| — | NCT02146300 | Mar → Jun 2014 | — | Oulu University Hospital | Unknown | No outcome recorded |
| — | NCT00622817 | Oct 2004 → Mar 2005 | bronchiolitis | Schneider Children's Medical Center, Israel | Completed | No outcome recorded |
| Comparator or background therapy7 trials | ||||||
| Phase 3 | NCT07299630 Background | Dec 2025 → May 2026 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT06443255 Comparator | Jul → Aug 2024 | — | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 4 | NCT05334017 Comparator | Sep 2022 → Mar 2023 | — | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 4 | NCT02557269 Background | May → Oct 2015 | seasonal allergic rhinitis | Association Asthma, Bulgaria | Unknown | No outcome recorded |
| Phase 4 | NCT00630474 Comparator | Jan 2004 → Apr 2005 | obstructive sleep apnea syndrome, rhinitis | University of Zurich | Completed | No outcome recorded |
| — | NCT05999955 Comparator | Dec 2022 → Apr 2023 | rhinitis, sinusitis | Huro Biotech Joint Stock Company | Completed | No outcome recorded |
| — | NCT05804123 Background | Oct 2021 → Apr 2024 | respiratory tract infectious disorder | Anabio R&D | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-10-23 | HALEON | Haleon launches Otrivin Nasal Mist: a new generation of nasal spray haleon.com ↗ |
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Xylometazoline | “OBJECTIVE: To evaluate the effects of xylometazoline hydrochloride 0.1% (Otrivin, GSK Consumer Healthcare SARL, Switzerland) for up to 7 days on QoL in participants with nasal...” PMID 38372128 ↗ Jan 202415“Group A participants received 4% Lidocaine and 0.1% Xylometazoline solution as intranasal spray” NCT04732104 ↗ “Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion.” NCT03439436 ↗ “bilateral application of xylometazoline nasal decongestant drops” NCT07299630 ↗ |
| Known as | Balminil | ChEMBL registry synonym — accepted as the source's own label CHEMBL312448 ↗ |
| Known as | Nazo-mist | ChEMBL registry synonym — accepted as the source's own label CHEMBL312448 ↗ |
| Known as | Neo-synephrine ii | ChEMBL registry synonym — accepted as the source's own label CHEMBL312448 ↗ |
| Known as | NSC-757378 | ChEMBL registry synonym — accepted as the source's own label CHEMBL312448 ↗ |
| Known as | Otradrops | ChEMBL registry synonym — accepted as the source's own label CHEMBL312448 ↗ |
| Known as | Otraspray | ChEMBL registry synonym — accepted as the source's own label CHEMBL312448 ↗ |
| Known as | Otrivin | “OBJECTIVE: To evaluate the effects of xylometazoline hydrochloride 0.1% (Otrivin, GSK Consumer Healthcare SARL, Switzerland) for up to 7 days on QoL in participants with nasal...” PMID 38372128 ↗ Jan 20243“Otrivin (Xylometazoline 0.05%) (Novartis VietNam, product declaration No. VN-15558-12) is a nasal-spraying decongestant” NCT05804123 ↗ “study drug Xylometazoline (0.1% nasal drops) (Otrivin, Novartis) (3 drops into each nostril)” NCT03424889 ↗ |
| Known as | Otrivin hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL312448 ↗ |
| Known as | Otrivine | “This is a longitudinal, open-label study evaluating the effect on QoL factors in participants with the common cold using Otrivine nasal spray (xylometazoline hydrochloride 0.1 percent” NCT05556148 ↗ |
| Known as | Otrivine hay fever for | ChEMBL registry synonym — accepted as the source's own label CHEMBL312448 ↗ |
| Known as | Xilometazolina | ChEMBL registry synonym — accepted as the source's own label CHEMBL312448 ↗ |
| Known as | Xylomet hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL312448 ↗ |
| Known as | xylometazoline HCL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00622817 ↗ |
| Known as | xylometazoline HCL = Otrivin nasal drops | “xylometazoline HCL = Otrivin nasal drops” NCT00622817 ↗ |
| Known as | xylometazoline hydrochloride | “OBJECTIVE: To evaluate the effects of xylometazoline hydrochloride 0.1% (Otrivin, GSK Consumer Healthcare SARL, Switzerland) for up to 7 days on QoL in participants with nasal...” PMID 38372128 ↗ Jan 2024 |
| Modality | Small molecule | — CHEMBL312448 ↗ |
| Route | Intranasal | “one nasal drop of xylometazoline HCL 0.05% to each nostril twice a day” NCT00622817 ↗ |